Uy Ear
Stock Analyst at Mizuho
(4.22)
# 426
Out of 5,147 analysts
78
Total ratings
52.08%
Success rate
18.36%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $24.56 | +42.51% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $132.25 | +32.33% | 11 | Dec 12, 2025 | |
| QURE uniQure | Maintains: Outperform | $60 → $33 | $15.63 | +111.13% | 6 | Dec 9, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.30 | +341.86% | 4 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $26.97 | +37.19% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.56 | +119.30% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $16.76 | +55.13% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $30.10 | +49.50% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $32.55 | +72.04% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $23.45 | +262.47% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $7.59 | +427.01% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $248.43 | -83.90% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.32 | +201.20% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.82 | +64.84% | 2 | Mar 1, 2023 |
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $24.56
Upside: +42.51%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $132.25
Upside: +32.33%
uniQure
Dec 9, 2025
Maintains: Outperform
Price Target: $60 → $33
Current: $15.63
Upside: +111.13%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.30
Upside: +341.86%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $26.97
Upside: +37.19%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.56
Upside: +119.30%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $16.76
Upside: +55.13%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $30.10
Upside: +49.50%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $32.55
Upside: +72.04%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $23.45
Upside: +262.47%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $7.59
Upside: +427.01%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $248.43
Upside: -83.90%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $3.32
Upside: +201.20%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.82
Upside: +64.84%